| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||
Net loss | |||||||||
-567,057 | -374,080 | -59,400 | -81,948 | -119,384 | 174,377 | 129,604 | 151,530 | 93,593 | 24,049 |
Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||
Impairments of goodwill, intangible assets, property and equipment | |||||||||
532,336 | 363,522 | 69,062 | 0 | 125,092 | 0 | 0 | - | - | - |
Depreciation expense | |||||||||
30,600 | 33,100 | 34,400 | 35,636 | 38,388 | 37,414 | 36,166 | 31,458 | 26,245 | 21,889 |
Amortization of intangible assets | |||||||||
32,600 | 41,400 | 30,700 | 26,124 | 27,295 | 27,658 | 24,413 | 20,346 | 14,530 | 11,327 |
Inventory write down | |||||||||
10,324 | 36,606 | 14,620 | 25,537 | 51,917 | 8,171 | 10,093 | - | - | - |
Stock-based compensation expense | |||||||||
15,846 | 19,927 | 20,310 | 20,535 | 21,675 | 18,770 | 19,038 | 8,179 | 5,156 | 5,136 |
Gain (Loss) on Disposition of Assets | |||||||||
2,300 | 0 | 0 | - | - | - | - | - | - | - |
Gain realized on previously held equity investment | |||||||||
1,567 | 0 | 120,392 | 0 | 0 | - | - | - | - | - |
Loss from unconsolidated subsidiary | |||||||||
-318 | 140 | -2,073 | 1,421 | 8,044 | -1,376 | 1,376 | 0 | 0 | - |
Payment of contingent consideration included in operating expense | |||||||||
- | - | - | - | - | - | - | 7,127 | 0 | 0 |
Contingent consideration benefit | |||||||||
-4,629 | 0 | 0 | - | - | - | - | -4,568 | 12,100 | 0 |
Deferred loan costs written off | |||||||||
- | - | - | 2,978 | 0 | 0 | 2,149 | 0 | 0 | 6,082 |
Accounts Receivable, Credit Loss Expense (Reversal) | |||||||||
3,152 | 3,342 | 2,903 | 485 | 4,358 | 2,492 | 2,925 | - | - | - |
Impairment of intangible assets | |||||||||
- | - | - | - | - | - | - | 1,161 | 0 | 0 |
Deferred income taxes | |||||||||
12,985 | 13,552 | -149 | 24,418 | 23,246 | 3,270 | -15,622 | 6,349 | 1,482 | 1,178 |
Gain on contribution of subsea rentals business | |||||||||
0 | 33,506 | 0 | 0 | - | - | - | - | - | - |
Noncash losses (gains) and other, net | |||||||||
4,040 | 1,086 | 3,886 | 4,389 | 3,867 | 4,109 | -1,842 | 2,108 | 4,300 | 2,998 |
Changes in operating assets and liabilities | |||||||||
Accounts receivable—trade | |||||||||
-49,732 | 4,833 | 64,844 | -29,450 | -145,753 | 44,727 | -1,188 | -12,872 | 62,350 | 13,132 |
Inventories | |||||||||
-54,265 | 60,903 | 66,646 | -57,294 | -344 | 34,051 | -23,042 | 100,268 | 90,634 | 5,745 |
Prepaid expenses and other assets | |||||||||
-621 | 7,980 | -12,462 | -1,071 | -3,576 | 4,107 | 20,415 | -15,636 | 10,477 | -2,278 |
Income tax receivable | |||||||||
0 | 0 | -30,929 | 32,801 | 0 | 0 | - | - | - | - |
Cost and estimated profit in excess of billings | |||||||||
4,632 | 1,273 | -171 | 1,897 | 2,215 | 8,742 | -16,705 | 5,403 | -5,210 | 2,550 |
Accounts payable, deferred revenue and other accrued liabilities | |||||||||
-48,056 | -4,192 | 52,142 | 3,799 | -111,264 | 62,772 | -1,475 | -4,781 | 56,256 | 14,167 |
Billings in excess of costs and estimated profits earned | |||||||||
2,279 | 1,329 | -2,245 | -3,865 | -6,629 | 10,240 | -11,034 | 12,341 | -2,752 | -4,440 |
Net cash provided by operating activities | |||||||||
104,144 | 2,407 | -40,033 | 64,742 | 155,913 | 269,966 | 211,393 | 137,941 | 39,275 | 65,981 |
Cash flows from investing activities | |||||||||
Distribution from unconsolidated subsidiary | |||||||||
- | - | - | - | - | - | 64,228 | 0 | 0 | - |
Capital expenditures for property and equipment | |||||||||
15,102 | 24,043 | 26,709 | 16,828 | 32,291 | 53,792 | 60,263 | 49,685 | 41,163 | 19,624 |
Payments to Acquire Businesses, Net of Cash Acquired | |||||||||
0 | 60,622 | 162,189 | 4,072 | 60,836 | 38,289 | 181,718 | 139,889 | 509,857 | 0 |
Return of investment in unconsolidated subsidiary | |||||||||
- | - | - | - | - | 9,240 | 0 | 0 | - | - |
Proceeds from sale of equity investment, property and equipment | |||||||||
43,237 | 9,258 | 1,971 | 9,763 | 1,821 | 12,150 | 964 | 5,051 | 906 | 670 |
Investment in unconsolidated subsidiary | |||||||||
0 | 0 | 1,041 | 0 | 0 | - | 112,241 | 0 | 0 | - |
Capitalized costs related to patents | |||||||||
- | - | - | - | - | - | - | - | - | 262 |
Net cash used in investing activities | |||||||||
28,135 | -75,407 | -187,968 | -11,137 | -91,306 | -70,691 | -289,030 | -184,523 | -550,114 | -19,216 |
Cash flows from financing activities | |||||||||
Borrowings of debt | |||||||||
137,000 | 221,980 | 107,431 | 0 | - | - | - | - | - | - |
Repayments of debt | |||||||||
256,900 | 211,783 | 0 | 0 | 120,077 | 98,415 | 715,131 | 454,019 | 61,973 | 407,360 |
Borrowings under Credit Facility due to acquisitions | |||||||||
- | - | - | - | - | - | - | - | 509,857 | 0 |
Borrowings under credit facility | |||||||||
- | - | - | - | 94,984 | 15,423 | 404,953 | 203,286 | 10,490 | 323,916 |
Issuance of Senior Notes | |||||||||
- | - | - | - | - | - | 403,250 | 0 | - | - |
Proceeds of IPO, net of offering costs | |||||||||
- | - | - | - | - | - | - | 256,381 | 0 | 0 |
Proceeds from concurrent private placement | |||||||||
- | - | - | - | - | - | - | 50,000 | 0 | 0 |
Payment of contingent consideration accrued at acquisition | |||||||||
- | - | - | - | - | - | 11,435 | 11,100 | 0 | 0 |
Purchased stock due to the Combination | |||||||||
- | - | - | - | - | - | - | - | - | 3,327 |
Repurchases of stock | |||||||||
1,094 | 2,777 | 4,742 | 623 | 6,438 | 96,632 | 4,316 | 56 | 54 | 25,162 |
Excess tax benefits from stock based compensation | |||||||||
- | - | - | - | -8 | 7,742 | 7,202 | 7,337 | 1,027 | 38 |
Proceeds from stock issuance | |||||||||
0 | 249 | 1,491 | 87,676 | 5,275 | 11,101 | 5,458 | 14,432 | 57,046 | 64,928 |
Payment of capital lease obligations | |||||||||
1,197 | 1,147 | 1,187 | 92 | 673 | 1,231 | 924 | 464 | 310 | 627 |
Deferred financing costs | |||||||||
0 | 0 | 2,430 | 766 | 0 | 6 | 12,003 | 15 | 5,935 | 6,671 |
Net cash provided by (used in) financing activities | |||||||||
-122,191 | 6,522 | 100,563 | 86,195 | -26,937 | -162,018 | 77,054 | 65,782 | 510,148 | -54,265 |
Effect of exchange rate changes on cash | |||||||||
582 | -1,497 | 8,232 | -14,627 | -5,000 | -260 | -898 | 1,315 | 891 | 954 |
Net increase (decrease) in cash, cash equivalents and restricted cash | |||||||||
10,670 | -67,975 | -119,206 | 125,173 | 32,670 | 36,997 | -1,481 | 20,515 | 200 | -6,546 |
Supplemental cash flow disclosures | |||||||||
Cash paid for interest | |||||||||
31,940 | 30,269 | 25,986 | 26,331 | 27,870 | 27,628 | 17,977 | 15,224 | 17,700 | 14,219 |
Cash paid (refunded) for income taxes | |||||||||
3,917 | 5,560 | -29,094 | -6,273 | 19,919 | 55,576 | 41,356 | 59,439 | 29,127 | 25,009 |
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] | |||||||||
Noncash activities | |||||||||
Acquisition via issuance of stock | |||||||||
0 | 0 | 177,972 | 0 | 0 | - | - | - | - | - |
Assets contributed for equity method investment | |||||||||
0 | 18,070 | 0 | 0 | - | - | - | - | - | - |
Note receivable related to equity method investment transaction | |||||||||
4,725 | 4,067 | 0 | 0 | - | - | - | - | - | - |
Insurance policy financed through notes payable | |||||||||
- | - | - | - | - | - | - | 6,348 | 1,717 | 3,809 |
Payment of contingent consideration via stock | |||||||||
- | - | - | - | - | - | 4,075 | 3,341 | 0 | 0 |
Accrued purchases of property and equipment | |||||||||
91 | 1,708 | 1,398 | 797 | 929 | 765 | 1,526 | 0 | 0 | - |
Accrued consideration for acquisition | |||||||||
0 | 4,650 | 0 | 0 | 1,070 | 0 | 0 | - | - | - |
Acquisition via contingent consideration and stock | |||||||||
- | - | - | - | - | - | - | - | 68,754 | 0 |